ALT Altimmune, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1326190 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY105.0%
TTM net income YoY7.3%
TTM EPS YoY25.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-230,461.0%
Net margin-214,861.0%
FCF margin—
EBITDA margin-230,187.8%
Returns
ROE-50.6%
ROA-42.0%
ROIC (approx.)-49.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets19.7%
Debt / equity0.15x
Current ratio18.55x
Interest coverage-57.76x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $26,000 | $5,000 | $5,000 | $5,000 | $5,000 |
| R&D expense | $27.02M | $18.66M | $16.19M | $18.41M | $14.96M | $17.24M | $15.83M | $19.78M |
| SG&A expense | $8.69M | $7.57M | $8.05M | $10.51M | $5.90M | $5.69M | $5.99M | $5.09M |
| Operating income | -$35.70M | -$26.23M | -$24.24M | -$28.89M | -$20.86M | -$22.92M | -$21.82M | -$24.87M |
| Interest expense | $1.12M | $1.10M | $1.07M | $876,000 | $495,000 | $264,000 | $1,000 | $1,000 |
| Pretax income | -$31.61M | -$22.82M | -$22.56M | -$27.36M | -$19.01M | -$22.15M | -$20.26M | -$23.18M |
| Income tax | — | — | — | $0 | $0 | $0 | -$681,000 | — |
| Net income | -$31.61M | -$22.82M | -$22.56M | -$27.36M | -$19.01M | -$22.15M | -$19.57M | -$23.18M |
| EBITDA | -$35.69M | -$26.21M | -$24.22M | -$28.87M | -$20.83M | -$22.89M | -$21.79M | -$24.83M |
| EPS (basic) | -0.15 | -0.12 | -0.18 | — | -0.21 | -0.27 | -0.26 | — |
| EPS (diluted) | -0.15 | -0.12 | -0.18 | — | -0.21 | -0.27 | -0.26 | — |
| Weighted avg. shares (diluted) | 205.27M | 185.44M | 124.46M | — | 89.42M | 81.48M | 75.55M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $28.89M | $63.01M | $97.60M | $43.76M | $61.28M | $183.15M | $49.15M | $36.97M |
| Short-term investments | $236.17M | $263.27M | $233.94M | $229.70M | $149.54M | — | $100.72M | $94.97M |
| Current assets | $275.77M | $334.81M | $334.68M | $278.19M | $216.62M | $188.42M | $155.26M | $137.25M |
| PP&E, net | $112,000 | $60,000 | $208,000 | $312,000 | $337,000 | $364,000 | $384,000 | $413,000 |
| Intangibles | — | — | — | — | — | — | — | $0 |
| Total assets | $495.65M | $527.21M | $335.63M | $279.93M | $218.45M | $190.35M | $157.26M | $139.31M |
| Current liabilities | $11.53M | $12.50M | $11.32M | $15.00M | $12.61M | $9.22M | $9.80M | $10.47M |
| Long-term debt | $34.99M | $34.74M | $34.51M | $34.29M | $14.45M | $14.33M | — | — |
| Total debt | $34.99M | $34.74M | $34.51M | $34.29M | $14.45M | $14.33M | — | — |
| Total liabilities | $52.08M | $53.00M | $51.64M | $55.04M | $32.85M | $28.98M | $15.10M | $15.80M |
| Shareholders' equity | $443.57M | $474.21M | $283.99M | $224.89M | $185.60M | $161.37M | $142.16M | $123.51M |
| Net debt | $6.10M | -$28.27M | -$63.10M | -$9.47M | -$46.83M | -$168.81M | — | — |
| Shares outstanding | 194.54M | 194.47M | 130.22M | 110.88M | 95.60M | 85.08M | 77.83M | 72.35M |
| Cash flow statement | ||||||||
| Operating cash flow | -$37.74M | -$24.22M | -$20.94M | -$19.45M | -$11.90M | -$19.35M | -$16.84M | -$18.27M |
| Capital expenditure | $64,000 | $32,000 | $21,000 | $1,000 | $0 | — | — | — |
| Free cash flow | -$37.81M | -$24.25M | -$20.96M | -$19.45M | -$11.90M | — | — | — |
| Investing cash flow | $3.54M | -$221.44M | -$3.69M | -$79.16M | -$149.32M | $101.11M | -$5.10M | $13.63M |
| Financing cash flow | $82,000 | $211.07M | $78.47M | $81.13M | $39.35M | $52.24M | $34.12M | $10.09M |
| Depreciation & amortization | $11,000 | $23,000 | $23,000 | $26,000 | $27,000 | $30,000 | $29,000 | $33,000 |
| Stock-based compensation | $2.87M | $2.79M | $3.38M | $4.94M | $3.55M | $3.57M | $4.01M | $3.35M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.